Actavis to buy Auden McKenzie for $465M
- The acquisition of Auden McKenzie, which will cost $465 million upfront in addition to a two-year royalty on one of Auden McKenzie's products, will make Actavis the largest supplier of generics in the United Kingdom (UK).
- All told. Actavis has more than 650 generics that are marketed in the UK, as well as 85 products in development, while Auden McKenzie has 175 generic and branded products, as well as 40 products in development.
- The deal is expected to close this quarter.
The acquisition of Auden McKenzie is another step for Actavis towards becoming a powerhouse pharma company, especially with its recent acquisition of Allergan ---the deal will close at the end of the year. When everything is factored into the equation, Actavis will have more than 1000 products available in the UK, with the majority of them being generics.
- Contract Pharma Actavis to Acquire Auden Mckenzie